Suppr超能文献

相似文献

1
Cytochrome P450 Enzymes as Drug Targets in Human Disease.
Drug Metab Dispos. 2024 May 16;52(6):493-497. doi: 10.1124/dmd.123.001431.
2
Updates on Mechanisms of Cytochrome P450 Catalysis of Complex Steroid Oxidations.
Int J Mol Sci. 2024 Aug 20;25(16):9020. doi: 10.3390/ijms25169020.
3
Cloning and tissue expression of cytochrome P450 2S1, 4V2, 7A1, 7B1, 8B1, 24A1, 26A1, 26C1, 27A1, 39A1, and 51A1 in marmosets.
Drug Metab Pharmacokinet. 2020 Apr;35(2):244-247. doi: 10.1016/j.dmpk.2019.11.008. Epub 2019 Dec 26.
4
Cytochrome Binds Tightly to Several Human Cytochrome P450 Enzymes.
Drug Metab Dispos. 2021 Oct;49(10):902-909. doi: 10.1124/dmd.121.000475. Epub 2021 Jul 30.
6
Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes.
J Biol Chem. 2019 Jul 12;294(28):10928-10941. doi: 10.1074/jbc.RA119.009305. Epub 2019 May 30.
8
The use of aromatase inhibitors in boys with short stature: what to know before prescribing?
Arch Endocrinol Metab. 2017 Jul-Aug;61(4):391-397. doi: 10.1590/2359-3997000000284.
9
A suite of activity-based probes for human cytochrome P450 enzymes.
J Am Chem Soc. 2009 Aug 5;131(30):10692-700. doi: 10.1021/ja9037609.
10
In vitro cytochrome P450-mediated metabolism of exemestane.
Drug Metab Dispos. 2011 Jan;39(1):98-105. doi: 10.1124/dmd.110.032276. Epub 2010 Sep 28.

引用本文的文献

1
Unmasking Conformationally Adaptable Lipids as Drug Receptors.
J Med Chem. 2025 Aug 28;68(16):16912-16920. doi: 10.1021/acs.jmedchem.5c01035. Epub 2025 Aug 11.
3
Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients.
PLoS One. 2025 Jun 10;20(6):e0325448. doi: 10.1371/journal.pone.0325448. eCollection 2025.
5
Brain Cytochrome P450: Navigating Neurological Health and Metabolic Regulation.
J Xenobiot. 2025 Mar 14;15(2):44. doi: 10.3390/jox15020044.
6
Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders.
Cancer Genomics Proteomics. 2025 Mar-Apr;22(2):285-305. doi: 10.21873/cgp.20502.
9
Breaking the Barriers of Therapy Resistance: Harnessing Ferroptosis for Effective Hepatocellular Carcinoma Therapy.
J Hepatocell Carcinoma. 2024 Jul 2;11:1265-1278. doi: 10.2147/JHC.S469449. eCollection 2024.
10
Steroidogenic cytochrome P450 enzymes as drug target.
Toxicol Res. 2024 Apr 22;40(3):325-333. doi: 10.1007/s43188-024-00237-0. eCollection 2024 Jul.

本文引用的文献

2
Non-steroidal CYP17A1 Inhibitors: Discovery and Assessment.
J Med Chem. 2023 May 25;66(10):6542-6566. doi: 10.1021/acs.jmedchem.3c00442. Epub 2023 May 16.
3
Cytochrome P450 and Other Drug-Metabolizing Enzymes As Therapeutic Targets.
Drug Metab Dispos. 2023 Aug;51(8):936-949. doi: 10.1124/dmd.122.001011. Epub 2023 Apr 11.
4
Pyridine-containing substrate analogs are restricted from accessing the human cytochrome P450 8B1 active site by tryptophan 281.
J Biol Chem. 2023 Apr;299(4):103032. doi: 10.1016/j.jbc.2023.103032. Epub 2023 Feb 17.
6
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis.
Mol Cancer Ther. 2022 Dec 2;21(12):1765-1776. doi: 10.1158/1535-7163.MCT-22-0115.
7
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.
Bioorg Med Chem Lett. 2022 Nov 1;75:128951. doi: 10.1016/j.bmcl.2022.128951. Epub 2022 Aug 27.
8
Nirmatrelvir Plus Ritonavir: First Approval.
Drugs. 2022 Apr;82(5):585-591. doi: 10.1007/s40265-022-01692-5.
9
Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
J Biol Chem. 2021 Aug;297(2):100969. doi: 10.1016/j.jbc.2021.100969. Epub 2021 Jul 15.
10
U.S. FDA Approved Drugs from 2015-June 2020: A Perspective.
J Med Chem. 2021 Mar 11;64(5):2339-2381. doi: 10.1021/acs.jmedchem.0c01786. Epub 2021 Feb 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验